MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
NanoViricides Interest Expense 2011-2026 | NNVC
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense NanoViricides
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125 K | 272 K | 356 K | 5.12 K | 85.4 K | 93.7 K | - | 185 K | 781 K | 1.04 M | 2.65 M | 3.09 M | 963 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.09 M | 5.12 K | 804 K |
Quarterly Interest Expense NanoViricides
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.5 K | 11.6 K | - | 32.4 K | 31.7 K | 41 K | - | 53.9 K | 83.1 K | 99.3 K | - | 108 K | 94 | 844 | 938 | 4.79 K | 2.63 K | 891 | 4.39 K | 495 | 37.3 K | 43.9 K | 37.3 K | 44.9 K | 4.13 K | - | 4.13 K | - | - | - | 15.7 K | 22.1 K | 25 K | 125 K | 49.4 K | 125 K | 245 K | 245 K | 490 K | 245 K | 245 K | 245 K | 245 K | 245 K | 247 K | 245 K | 247 K | 245 K | 126 K | 121 K | 126 K | 121 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 490 K | 94 | 105 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
1.14 M | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
Voyager Therapeutics
VYGR
|
1.65 M | $ 3.96 | -4.12 % | $ 232 M | USA |
 |
VistaGen Therapeutics
VTGN
|
5 K | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | USA |
 |
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | USA |
 |
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
11.8 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
527 K | $ 6.37 | 2.66 % | $ 1.07 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
5.72 K | $ 2.72 | -2.86 % | $ 4.63 M | USA |
 |
XBiotech
XBIT
|
1.46 M | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
484 K | $ 54.48 | -1.89 % | $ 4.24 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
-24.3 M | $ 5.4 | -3.05 % | $ 866 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
-753 K | $ 4.04 | -6.26 % | $ 171 M | USA |
 |
Xencor
XNCR
|
-73 K | $ 11.42 | -7.23 % | $ 848 M | USA |
 |
XOMA Corporation
XOMA
|
12.2 M | $ 30.17 | -1.18 % | $ 364 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
22nd Century Group
XXII
|
-207 K | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | USA |
 |
Zai Lab Limited
ZLAB
|
3.54 M | $ 18.0 | 2.8 % | $ 19.7 B | China |
|
Enlivex Therapeutics Ltd.
ENLV
|
874 K | $ 1.05 | -3.67 % | $ 21.5 M |  Israel |
 |
Enochian Biosciences
ENOB
|
122 K | - | - | $ 40.5 M | USA |